Open-source automated insulin delivery (AID) systems in patients with type 1 diabetes was studied in the CREATE trial and is discussed by Dr Martin de Bock (University of Otago, Christchurch, New Zealand). Open-source AID systems were developed by people with diabetes and shared openly. They combine an insulin pump, continuous glucose monitor and an algorithm that adjusts insulin delivery automatically every five minutes with the purpose of keeping glucose levels in target range.
The abstract entitled ‘The CREATE Trial: Randomized Clinical Trial Comparing Open-Source Automated Insulin Delivery with Sensor Augmented Pump Therapy in Type 1 Diabetes‘ was presented at the 82nd American Diabetes Association Scientific Session, June 3-7, 2022.
Questions:
- Could you give us a brief overview of open-source automated insulin delivery systems (AID) and sensor-augmented pump therapy? (0:15)
- What were the aims, design and patient population of the CREATE trial? (0:50)
- How did the two treatment arms compare in terms of time in range? (1:23)
- What were study findings in terms of hypoglycaemia, diabetic ketoacidosis events, and treatment discontinuation? (1:51)
- Which patients were most likely to benefit from AID? (2:16)
Disclosures: Martin de Bock has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.
Filmed as a highlight of ADA 2022.
